Recent headlines around proposed US tariffs on European countries highlight just how volatile the global trade environment remains. As reported this week  in Fierce Pharma , potential new duties on several European nations raised questions about the future of US–EU trade relations and potential impacts on pharmaceuticals. For sponsors running global clinical trials, this kind of uncertainty can translate into real operational risk: fluctuating costs, sourcing delays, and regu

Client Overview A global biopharmaceutical company approached CSI to support a Phase III oncology study requiring Opdivo (nivolumab) as a comparator. The study spanned 4 countries across North America, Europe and Asia-Pacific, with a target enrolment of over 500 patients. The client’s main objective was to ensure timely delivery of branded Opdivo for multiple trial sites while maintaining transparent, full chain of custody and documentation.   Challenge There were several key